E A M Heijnsdijk
Affiliation: Erasmus MC
Country: The Netherlands
- Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trialSepideh Saadatmand
Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
BMC Cancer 12:440. 2012..The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density...
- Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combinedEveline A M Heijnsdijk
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012..Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines...
- Quality-of-life effects of prostate-specific antigen screeningEveline A M Heijnsdijk
Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
N Engl J Med 367:595-605. 2012..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain...
- Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerE A M Heijnsdijk
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Br J Cancer 101:1833-8. 2009..Overdetection and overtreatment are substantial unfavourable side effects with consequent healthcare costs. In this study the effects of introducing widespread PSA screening is evaluated...
- Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factorsE M Wever
Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
Br J Cancer 108:1971-7. 2013..We quantified how the benefits and harms of immediate treatment vary according to the prognostic factors of clinical T-stage, Gleason score, and patient age...
- To be screened or not to be screened? Modeling the consequences of PSA screening for the individualE M Wever
Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands
Br J Cancer 107:778-84. 2012..We estimated benefits and adverse effects of PSA screening for individuals who are deciding whether or not to be screened...
- Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervalsN T van Ravesteyn
Department of Public Health, Erasmus MC, PO Box 2040, Rotterdam 3000 CA, The Netherlands
Br J Cancer 105:1082-8. 2011..In this study, the trial is simulated in order to gain insight into the results of the trial and to predict the effect of different screening intervals on breast cancer mortality...
- Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deathsR de Gelder
Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
Br J Cancer 104:1214-20. 2011..Because the radiation risk increases with lower exposure age, advancing the lower age limit may affect the balance between screening benefits and risks. The present study explores the benefit-risk ratio of screening before age 50...